文献速递冠心病

秋水仙碱对急性冠脉综合征患者冠脉斑块稳定性的影响:COLOCT随机临床试验

Effect of Colchicine on Coronary Plaque Stability in Acute Coronary Syndrome as Assessed by Optical Coherence Tomography: The COLOCT Randomized Clinical Trial.
PubMed 文献 · Circulation · 2024-08-21

COLOCT试验为前瞻性、单中心、随机双盲研究,纳入128例急性冠脉综合征且光学相干断层扫描(OCT)检出脂质丰富斑块(脂质池弧度>90°)的患者,随机接受秋水仙碱0.5 mg每日一次或安慰剂治疗12个月。结果显示秋水仙碱显著增加最小纤维帽厚度,并降低平均脂质弧度、巨噬细胞平均角度扩展及高敏C反应蛋白、白介素-6、髓过氧化物酶水平,提示其有利于斑块稳定。

要点

  • 秋水仙碱0.5 mg每日一次治疗12个月可增加ACS患者最小纤维帽厚度。
  • 秋水仙碱降低平均脂质弧度、巨噬细胞角度扩展及炎症标志物水平。
  • OCT评估提示秋水仙碱对冠脉斑块稳定具有有利影响。

核心结论

  • 在急性冠脉综合征患者中,秋水仙碱对OCT评估的冠脉斑块稳定产生有利影响。

研究设计与样本

  • 前瞻性、单中心、随机、双盲临床试验,纳入128例18至80岁急性冠脉综合征且OCT检出脂质丰富斑块(脂质池弧度>90°)的患者。
  • 患者按1:1随机接受秋水仙碱0.5 mg每日一次或安慰剂治疗12个月。
  • 主要终点为从基线至12个月随访时最小纤维帽厚度的变化。
  • 秋水仙碱组52例和安慰剂组52例完成研究;128例患者平均年龄58.0±9.8岁,女性占25.0%。

主要发现

  • 与安慰剂相比,秋水仙碱显著增加最小纤维帽厚度(51.9 [95% CI, 32.8 to 71.0] μm 对 87.2 [95% CI, 69.9 to 104.5] μm;差值34.2 [95% CI, 9.7 to 58.6] μm;P=0.006)。
  • 秋水仙碱降低平均脂质弧度(-25.2° [95% CI, -30.6° to -19.9°] 对 -35.7° [95% CI, -40.5° to -30.8°];差值-10.5° [95% CI, -17.7° to -3.4°];P=0.004)。
  • 秋水仙碱降低巨噬细胞平均角度扩展(-8.9° [95% CI, -13.3° to -4.6°] 对 -14.0° [95% CI, -18.0° to -10.0°];差值-6.0° [95% CI, -11.8° to -0.2°];P=0.044)。
  • 秋水仙碱降低高敏C反应蛋白水平(几何均值比0.6 [95% CI, 0.4 to 1.0] 对 0.3 [95% CI, 0.2 to 0.5];差值0.5 [95% CI, 0.3 to 1.0];P=0.046)。
  • 秋水仙碱降低白介素-6水平(几何均值比0.8 [95% CI, 0.6 to 1.1] 对 0.5 [95% CI, 0.4 to 0.7];差值0.6 [95% CI, 0.4 to 0.9];P=0.025)和髓过氧化物酶水平(几何均值比1.0 [95% CI, 0.8 to 1.2] 对 0.8 [95% CI, 0.7 to 0.9];差值0.8 [95% CI, 0.6 to 1.0];P=0.047)。

临床怎么用

  • 对于急性冠脉综合征且OCT检出脂质丰富斑块的患者,可考虑使用秋水仙碱0.5 mg每日一次以促进斑块稳定。

局限性

  • 本研究为单中心试验,完成研究患者共104例(秋水仙碱组52例、安慰剂组52例),样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Colchicine has been approved to reduce cardiovascular risk in patients with coronary heart disease on the basis of its potential benefits demonstrated in the COLCOT (Colchicine Cardiovascular Outcomes Trial) and LoDoCo2 (Low-Dose Colchicine 2) studies. Nevertheless, there are limited data available about the specific impact of colchicine on coronary plaques. METHODS: This was a prospective, single-center, randomized, double-blind clinical trial. From May 3, 2021, until August 31, 2022, a total of 128 patients with acute coronary syndrome aged 18 to 80 years with lipid-rich plaque (lipid pool arc >90°) detected by optical coherence tomography were included. The subjects were randomly assigned in a 1:1 ratio to receive either colchicine (0.5 mg once daily) or placebo for 12 months. The primary end point was the change in the minimal fibrous cap thickness from baseline to the 12-month follow-up. RESULTS: Among 128 patients, 52 in the colchicine group and 52 in the placebo group completed the study. The mean age of the 128 patients was 58.0±9.8 years, and 25.0% were female. Compared with placebo, colchicine therapy significantly increased the minimal fibrous cap thickness (51.9 [95% CI, 32.8 to 71.0] μm versus 87.2 [95% CI, 69.9 to 104.5] μm; difference, 34.2 [95% CI, 9.7 to 58.6] μm; P=0.006), and reduced average lipid arc (-25.2° [95% CI, -30.6° to -19.9°] versus -35.7° [95% CI, -40.5° to -30.8°]; difference, -10.5° [95% CI, -17.7° to -3.4°]; P=0.004), mean angular extension of macrophages (-8.9° [95% CI, -13.3° to -4.6°] versus -14.0° [95% CI, -18.0° to -10.0°]; difference, -6.0° [95% CI, -11.8° to -0.2°]; P=0.044), high-sensitivity C-reactive protein level (geometric mean ratio, 0.6 [95% CI, 0.4 to 1.0] versus 0.3 [95% CI, 0.2 to 0.5]; difference, 0.5 [95% CI, 0.3 to 1.0]; P=0.046), interleukin-6 level (geometric mean ratio, 0.8 [95% CI, 0.6 to 1.1] versus 0.5 [95% CI, 0.4 to 0.7]; difference, 0.6 [95% CI, 0.4 to 0.9]; P=0.025), and myeloperoxidase level (geometric mean ratio, 1.0 [95% CI, 0.8 to 1.2] versus 0.8 [95% CI, 0.7 to 0.9]; difference, 0.8 [95% CI, 0.6 to 1.0]; P=0.047). CONCLUSIONS: Our findings suggested that colchicine resulted in favorable effects on coronary plaque stabilization at optical coherence tomography in patients with acute coronary syndrome. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04848857.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Yu, Yang, Dong, et al. Effect of Colchicine on Coronary Plaque Stability in Acute Coronary Syndrome as Assessed by Optical Coherence Tomography: The COLOCT Randomized Clinical Trial. Circulation. 2024. PMID: 39166327. doi:10.1161/CIRCULATIONAHA.124.069808

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。